Camrelizumab Plus Chemotherapy + placebo+chemotherapy
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Triple Negative Breast Cancer
Conditions
Triple Negative Breast Cancer
Trial Timeline
Dec 9, 2020 → Mar 5, 2024
NCT ID
NCT04613674About Camrelizumab Plus Chemotherapy + placebo+chemotherapy
Camrelizumab Plus Chemotherapy + placebo+chemotherapy is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Triple Negative Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04613674. Target conditions include Triple Negative Breast Cancer.
What happened to similar drugs?
1 of 20 similar drugs in Triple Negative Breast Cancer were approved
Approved (1) Terminated (1) Active (18)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04613674 | Phase 3 | Completed |
Competing Products
20 competing products in Triple Negative Breast Cancer